(Inhibition of NF-kB Signaling in Melanoma Therapy) A Phase I/II Clinical Trial of PS-341, a Proteasome Inhibitor, in Combination With an Extended Continuous Oral Schedule of Temozolomide in Patients With Advanced Refractory Solid Tumors With the Phase II Component Only in Patients With Melanoma

Trial Profile

(Inhibition of NF-kB Signaling in Melanoma Therapy) A Phase I/II Clinical Trial of PS-341, a Proteasome Inhibitor, in Combination With an Extended Continuous Oral Schedule of Temozolomide in Patients With Advanced Refractory Solid Tumors With the Phase II Component Only in Patients With Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2012

At a glance

  • Drugs Bortezomib (Primary) ; Temozolomide (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Aug 2012 Actual patient number changed from 50 to 47 as reported by ClinicalTrials.gov. (NCT00512798)
    • 02 Aug 2012 Actual patient number changed from 50 to 47 as reported by ClinicalTrials.gov. (NCT00512798)
    • 02 Aug 2012 Actual end date changed from 1 Feb 2010 to 1 Mar 2008 as reported by ClincialTrials.gov. (NCT00512798)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top